Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
-
- Katelyn A Pastick
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota
-
- Elizabeth C Okafor
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota
-
- Fan Wang
- Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota
-
- Sarah M Lofgren
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota
-
- Caleb P Skipper
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota
-
- Melanie R Nicol
- Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota
-
- Matthew F Pullen
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota
-
- Radha Rajasingham
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota
-
- Emily G McDonald
- Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Canada
-
- Todd C Lee
- Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Canada
-
- Ilan S Schwartz
- Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta
-
- Lauren E Kelly
- Department of Pediatrics and Child Health, Department of Pharmacology, University of Manitoba, Winnipeg, Canada
-
- Sylvain A Lother
- Department of Medicine, Sections of Critical Care and Infectious Diseases, University of Manitoba, Winnipeg, Canada
-
- Oriol Mitjà
- Fight AIDS and Inf Dis Foundation, Hospital Germans Trias i Pujol, Barcelona, Spain
-
- Emili Letang
- Department of Infectious Diseases, Hospital del Mar/Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
-
- Mahsa Abassi
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota
-
- David R Boulware
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota
抄録
<jats:title>Abstract</jats:title><jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.</jats:p>
収録刊行物
-
- Open Forum Infectious Diseases
-
Open Forum Infectious Diseases 7 (4), 2020-04-01
Oxford University Press (OUP)